March 25, 2024 06:34 AM EDT
Pharma
FDA+

Es­pe­ri­on eyes new com­mer­cial push for cho­les­terol-low­er­ing drugs af­ter big FDA la­bel ex­pan­sion

Amber Tong

Es­pe­ri­on has se­cured ma­jor FDA la­bel ex­pan­sions for its two cho­les­terol-low­er­ing drugs, a reg­u­la­to­ry mile­stone that it says opens up a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times